The PACE Foundation

02/20/2026

Healing happens.

Recruited on Instagram by Elana Meyers Taylor, the Notre Dame track champion only took up bobsled last year. It’s far from the biggest challenge she’s overcome.

02/10/2026

Jadin O'Brien battled a rare disease called PANDAS, was a star heptathlete and now an Olympic bobsledder

02/05/2026

Aetna has updated its medical policy to include PANS/PANDAS, allowing coverage when IVIG is considered a medically necessary treatment.

01/22/2026

Please share this far and wide!

In our latest CME webinar, Dr. Juliette Madan equips psychiatrists with practical tools to recognize the signs of the neuroinflammatory conditions, PANS/PANDAS, conduct effective evaluations, and support evidence-informed treatment planning. Watch now at https://pandasppn.org/cme.

12/16/2025

In an observational study, teens who took the antibiotic doxycycline, which is a common prescription for acne, had a reduced risk of developing schizophrenia. Because this is an observational study, we don't yet know the mechanism, but doxycycline can cross the blood-brain barrier (and affect the gut microbiome, as well), and has also previously been linked with better life outcomes for schizophrenia survivors. https://www.sciencealert.com/common-acne-medication-linked-with-30-lower-schizophrenia-risk

12/04/2025

Clicking the link will take the viewer to the current moment while livestreaming. It is possible to scroll to the beginning while it is still livestreaming. Once the session is complete the entire recording should still be accessible.

The Advisory Committee on Immunization Practices (ACIP) is a federal advisory committee that develops recommendations on the use of vaccines in the civilian ...

11/12/2025

https://bbc.in/463flGZ

Here’s how a common throat infection can rewire children's brains: https://bbc.in/463flGZ

11/06/2025

Always pay attention to the immune impact.

Antibiotic Doxycycline May Cut Schizophrenia Risk

New research suggests that the antibiotic doxycycline may have unexpected protective effects against schizophrenia.

Adolescents who received the drug were substantially less likely to develop the disorder later in life, possibly due to doxycycline’s influence on brain inflammation and development.

The study highlights inflammation as a key factor in schizophrenia risk and points to the potential of repurposing safe, existing drugs for prevention.

While the data are observational, the results open promising new directions for mental health research.

08/03/2025

PANS is not just a pediatric disorder. There is zero age requirement for a PANS diagnosis.
Learn more about PANS/PANDAS
www.aspire.care

06/13/2025

💙 A Victory for the PANS/PANDAS Community! 💙�

Louisiana just passed the Gillian Guiffreda Act, requiring insurance companies to cover the treatment of PANS/PANDAS — a massive step forward in helping children access the care they need and deserve.�

This law was passed with unanimous support, showing the power of advocacy, science, and families speaking up.

👏 Join us in celebrating this win and sending congrats to all the advocates and families whose hard work made this happen!

🗞️ Read the full news story here - https://www.wafb.com/2025/06/10/its-fight-worth-fighting-gillian-guiffreda-act-now-awaits-governors-signature-after-passing-with-unanimous-support-through-legislature/

💬 Drop a comment below if your state still needs a law like this 👇��

📲 Follow PACE to stay updated on legislative progress, treatment breakthroughs, and ways you can help make change happen

05/28/2025

📣 BIG NEWS for the PANS/PANDAS Community!

While the data from the IVIG trial is under review, we are pleased that Octapharma has officially released a statement regarding findings accumulated during the IVIG trial. Although the journey isn't over, the news brings hope. 💙

✅ Children who received PANZYGA® showed overall improvement.

📊 While the primary treatment measurement showed improvement, it was just short of the threshold for “statistical significance.”

🎯 The secondary treatment measurement showed even greater improvement which did achieve “statistical significance.” 🙌

➡️ While the review process may take additional time before any decisions about the IVIG trial are finalized, the trial is a meaningful step forward for treatment options and recognition of these conditions.

Octapharma USA President Flemming Nielsen stated:�"PANS is a very challenging disease for the medical community and families. Parents are confronted with the challenge of seeing their children afflicted with sudden-onset, debilitating, and difficult to treat OCD as well as other behavioral and cognitive issues. Octapharma looks forward to bringing relief to children and their families in the near future."

👏 Thank you to Octapharma, as well as the families, researchers, advocates, and dedicated medical professionals who helped make this trial possible.

🔔 Stay informed - To get IVIG trial updates and other news, sign up for our PACE newsletter via the link in our bio! 💌

🔗 Read the full announcement and Octapharma’s statement — https://pacefoundation4kids.org/ivig-trial-update/

Send a message to learn more